A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Advanced Urothelial Carcinoma Clinical Trial

Official title:

A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05929235
• Other study ID #: FX-909-CLINPRO-1
• Status: Recruiting
• Phase: Phase 1
• Start date: August 24, 2023
• Est. completion date: January 30, 2027

Study information

• Verified date: March 2024
• Source: Flare Therapeutics Inc.
• Contact: Melissa Moles, VP Clinical Operations
• Phone: 6173722515
• Email: clinops[@]flaretx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma.

The main question[s] it aims to answer are:

• Is FX-909 safe and tolerable

• What is the right dose level for patients

Participants will be asked to take FX-909 daily , in tablet form and record any outcomes from taking the drug. Participants will also be asked to return for multiple site visits for various blood tests and to collect blood and tumor samples as well as have regular CT/MRI scans

Description:

This is an open-label Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of FX-909 given orally (PO) in patients with advanced solid malignancies. Initially, FX-909 will be given in a dose-escalation phase (Part A) to determine the preliminary recommended phase 2 dose (RP2D). Part B will be a monotherapy expansion phase to further evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of FX-909 in patients with locally advanced (unresectable) and metastatic urothelial carcinoma. Throughout the study patients will be treated in 28-day cycles.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: January 30, 2027
• Est. primary completion date: September 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

1. Able to understand and willing to sign an informed consent.

2. Age = 18 years

3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

4. Part A (Dose Escalation): Histologically or cytologically diagnosed, locally advanced (unresectable) or metastatic solid malignancies that have progressed after all available standard therapy for the specific tumor type, or for which no standard therapy exists. Patients for whom standard therapies are intolerable or considered inappropriate by the Investigator are eligible.

Part B (Expansion): Histologically or cytologically diagnosed, locally advanced (unresectable) or metastatic urothelial carcinoma with defined genetic alterations. Patients in Part B must have progressed after all available standard therapy (eg, anti- programmed cell death (ligand) 1 [PD(L)1], antibody-drug conjugate[s], and platinum-based doublet chemotherapy), been unable to tolerate standard therapy, or be considered inappropriate for standard therapy by the Investigator.

5. Part A (Dose Escalation): Patients with or without measurable disease (as defined by RECIST version 1.1) will be eligible for enrollment.

Part B (Expansion): Patients must have measurable disease per RECIST version 1.1 with = 1 site of measurable disease that has not been previously irradiated or has progressed after radiation therapy.

6. An archival, paraffin-embedded, formalin-fixed, tumor sample (see Laboratory Manual for details) that is no more than 30 months old at the time of screening. If an archival tumor sample is not available or is older than 30 months, then the patient must consent to provide a fresh biopsy during screening.

7. Screening laboratory values meet the criteria outlined in the protocol. Hematologic criteria may be met with transfusion of blood products or administration of G-CSF, provided they are not given within 7 days of C1D1.

Exclusion Criteria:

1. Female patients who are pregnant (confirmed with a positive pregnancy test) or breastfeeding.

2. Prior anticancer chemotherapy or small molecule targeted therapy, either investigational or commercially approved and available, within 2 weeks or 5 half-lives (whichever is shorter) prior to the start of study drug administration. When the most recent therapy was a biological therapy (including antibody-drug conjugates), an immune-checkpoint inhibitor (eg, anti-PD(L)1 or anti-CTLA4), or immune agonist, patients should wait 4 weeks before starting therapy with FX-909.

3. Prior therapy directly inhibiting PPARG or RXRA.

4. Adverse events from prior therapy that have not returned to baseline or stabilized at Grade 1 (except alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade = 2 neuropathy) prior to study drug administration.

5. Prior major surgery (excluding placement of vascular access) within 4 weeks before study drug administration.

6. Prior radiation therapy with an inadequate washout between the last dose and the start of study drug, defined as follows: 1) at least 2 weeks for palliative radiation to the extremities for osseous bone metastases is required; and 2) at least 4 weeks for radiation to non-extremity sites is required.

7. History of another malignancy in the previous 2 years, unless cured by surgery alone and continuously disease free. Exceptions include appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, melanoma in situ status-post full-thickness resection without recurrence, Stage 1 uterine cancer, localized prostate cancer that has been treated surgically with curative intent and presumed cured, or other malignancies with an expected curative outcome.

8. QT Interval Corrected Using Fridericia's Formula (QTcF) > 470 msec in screening, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives.

9. Known active diagnosis of lipodystrophy/lipoatrophy, or an ongoing need to receive medications known to cause lipodystrophy/lipoatrophy

10. Any active uncontrolled systemic bacterial, viral, or fungal infection requiring treatment.

11. Known history of human immunodeficiency virus (HIV) seropositivity. Those who have no detectable viral load on highly active antiretroviral therapy (HAART) are permitted.

12. Patients with chronic hepatitis B virus (HBV) infection (indicated by a positive HBV surface antigen and/or hepatitis B core antibody). Patietns are permitted with either universal prophylaxis or a pre-emptive treatment approach consistent with regional or national guidelines for patients who receive anticancer therapies.

13. Active hepatitis C virus (HCV) infection. Those who have completed curative therapy for HCV and have no detectable viral load are permitted.

14. Prior diagnosis of chronic or recurrent (> 1 episode) pancreatitis at any time or a diagnosis of acute pancreatitis within the 6 months prior to screening

15. Significant impairment of lung function indicated by resting oxygen saturations below 92% on room air or requiring chronic use of ambulatory supplemental oxygen.

16. Uncontrolled or symptomatic central nervous system (CNS) metastases, leptomeningeal disease, or carcinomatous meningitis. Asymptomatic brain metastasis is allowed if they have been stable after appropriate radiotherapy for 1 month.

17. Need for treatment with high doses of oral or intravenous steroids (> 10 mg/day prednisone or equivalent). Physiologic doses of corticosteroids for treatment of endocrinopathies may be continued if the patient is on a stable dose for at least 1 month.

18. Need or anticipated need for treatment with a prohibited therapy described in the protocol during the treatment phase of this study

19. Concurrent participation in any other investigational therapeutic study

20. History of any of the following cardiovascular diseases:

• Recent history (within the 6 months prior to screening) of serious uncontrolled cardiac arrhythmia (including atrial fibrillation without adequate rate control) or clinically significant ECG abnormalities including second-degree (Type II) or third-degree atrioventricular node block

• Documented cerebrovascular event (stroke or transient ischemic attack), cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting, or bypass grafting within the 6 months prior to enrollment

• Congestive heart failure (Class III or IV) as defined by the New York Heart Association functional classification system

• Recent history (within the past 6 months) of symptomatic pericarditis

21. Thromboembolic events and/or bleeding disorders = 28 days (eg, deep vein thrombosis or pulmonary embolism) prior to the first dose of study drug

22. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which, in the Investigator's opinion, makes it undesirable for the patient to participate in the study or would jeopardize compliance with the protocol.

23. Patients with type 1 diabetes mellitus, or type 2 diabetes mellitus that is not adequately controlled with diet, exercise, or oral hypoglycemic agents and/or injectable agents other than insulin (as defined by HbA1c and fasting plasma glucose criteria in Table 6. Patients taking insulin are excluded from the study. Medication for type 2 diabetes mellitus should have remained stable for the past 14 days prior to screening).

24. Known hypersensitivity to FX-909 or any of its excipients (see Table 7 for the list of excipients)

25. Patients with gastrointestinal disorders that may interfere with the ability to swallow tablets or absorb study medication

26. Patient is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is a member of the study site or Sponsor staff directly involved with this study, unless prospective Institutional Review Board (IRB) or Ethics Committee (EC) approval (by chair or designee) is given allowing exception to this criterion for a specific patient.

27. Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before study entry.

28. Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of the patient's safety or study results.

Related Conditions & MeSH terms

• Advanced Solid Tumors Cancer
• Advanced Urothelial Carcinoma
• Carcinoma
• Carcinoma, Transitional Cell
• Open Label
• Oral Drug Administration

Intervention

Drug:
• FX-909
FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.

Locations

Country	Name	City	State
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Mass General Cancer Center	Boston	Massachusetts
United States	UNC Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina
United States	The Cleveland Clinic Foundation	Cleveland	Ohio
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	Yale Cancer Center	New Haven	Connecticut
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Memorial Slone Kettering Cancer Center	New York	New York
United States	New Experimental Therapeutics of San Antonio (NEXT)	San Antonio	Texas
United States	South Texas Accelerated Research Therapeutics (START)	San Antonio	Texas
United States	HonorHealth	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Flare Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess dose-limiting toxicities, the incidence and severity of adverse events and serious adverse events associated with FX-909 (Safety and Tolerability)	Incidence of dose-limiting toxicities (DLTs); Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)	through study completion, an average of 3 years
Secondary	To define the preliminary recommended phase 2 dose of FX-909, and/or maximum tolerated dose (MTD)	Assess patients' safety measures (AEs/SAEs) in comparison with patients' objective response rates	through study completion, an average of 3 years
Secondary	To characterize the pharmacokinetic profile of FX-909 in patients with advanced solid malignancies	Plasma pharmacokinetic parameters of FX-909 via AUC	through study completion, an average of 3 years
Secondary	To characterize the pharmacokinetic profile of FX 909 in patients with advanced solid malignancies	Plasma pharmacokinetic parameters of FX-909, via Cmax	through study completion, an average of 3 years
Secondary	To characterize the pharmacokinetic profile of FX 909 in patients with advanced solid malignancies	Plasma pharmacokinetic parameters of FX-909, via Tmax	through study completion, an average of 3 years
Secondary	To characterize the pharmacokinetic profile of FX 909 in patients with advanced solid malignancies	Plasma pharmacokinetic parameters of FX-909 via T½	through study completion, an average of 3 years
Secondary	To characterize the pharmacokinetic profile of FX 909 in patients with advanced solid malignancies	Plasma pharmacokinetic parameters of FX-909 via renal clearance in urine	through study completion, an average of 3 years
Secondary	To characterize the pharmacokinetic profile of FX 909 in patients with advanced solid malignancies	Plasma pharmacokinetic parameters of FX-909 via percentage of FX-909 in urine	through study completion, an average of 3 years
Secondary	To evaluate preliminary antitumor activity of FX 909 in patients with advanced solid malignancies	Objective response rate (ORR)	through study completion, an average of 3 years
Secondary	To evaluate preliminary antitumor activity of FX 909 in patients with advanced solid malignancies	Duration of Response (DoR)	through study completion, an average of 3 years
Secondary	To evaluate preliminary antitumor activity of FX 909 in patients with advanced solid malignancies	Time to response	through study completion, an average of 3 years
Secondary	To evaluate preliminary antitumor activity of FX 909 in patients with advanced solid malignancies	Disease Control Rate (DCR)	through study completion, an average of 3 years
Secondary	To evaluate preliminary antitumor activity of FX 909 in patients with advanced solid malignancies	Progression-Free Survival (PFS) based on Investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria	through study completion, an average of 3 years
Secondary	To evaluate preliminary antitumor activity of FX 909 in patients with advanced solid malignancies	Overall survival (OS)	through study completion, an average of 3 years